Global Lymphoma Therapeutics Market to Reach $25.2 Billion by 2030
The global market for Lymphoma Therapeutics estimated at US$14.9 Billion in the year 2022, is projected to reach a revised size of US$25.2 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2022-2030. Non-Hodgkin Lymphoma (NHL), one of the segments analyzed in the report, is projected to record 6.5% CAGR and reach US$20.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hodgkin Lymphoma (HL) segment is readjusted to a revised 7.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $4.1 Billion, While China is Forecast to Grow at 10.9% CAGR
The Lymphoma Therapeutics market in the U.S. is estimated at US$4.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.Select Competitors (Total 93 Featured) -
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- Chugai Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Forma Therapeutics, Inc.
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals
- Transgene SA
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Lymphoma Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Cancer Evolves Into the Global Epidemic
- Global New Cancer Incidence (In Million) for the Year 2020
- COVID-19 Extends a Major Setback to the World’s Battle Against Cancer
- Lymphoma: Disease Causes, Risks, Types, Symptoms, Diagnosis & Survival
- New Cases of Leukemia, Lymphoma and Myeloma in the U.S. for the Year 2020
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
3. MARKET TRENDS & DRIVERS
- Targeted Therapies Grow in Popularity for Treating Lymphoma
- CT Imaging: The Gold Standard & Workhorse of Lymphoma Diagnoses & Monitoring
- 'Liquid Biopsy' Rises in Prominence Among All Other Types of Lymph Node Biopsies
- Advancements in the Field of Genomics Brings Hope for the Development of More Potent Cancer
- What Are the Approved Drugs for Lymphoma?
- Artificial Intelligence Helps Speed Up & Automate Lymphoma Diagnosis
- Global Market for AI in Healthcare (US$ Billion) for Years 2020, 2022 & 2024
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Hodgkin Lymphoma (HL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Non-Hodgkin Lymphoma (NHL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for Revlimid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 15: World 18-Year Perspective for Rituxan / MabThera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 18: World 18-Year Perspective for Imbruvica by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 21: World 18-Year Perspective for Keytruda by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 24: World 18-Year Perspective for Adcetris by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 27: World 18-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 28: World Lymphoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
UNITED STATES
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 31: USA 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 34: USA 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 37: Canada 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 40: Canada 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
JAPAN
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 43: Japan 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 46: Japan 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
CHINA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 49: China 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 52: China 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
EUROPE
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 55: Europe 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 58: Europe 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 61: Europe 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
FRANCE
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 64: France 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 67: France 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
GERMANY
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 70: Germany 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 73: Germany 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 76: Italy 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 79: Italy 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 82: UK 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 85: UK 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Spain Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 88: Spain 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Spain Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 91: Spain 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Russia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 94: Russia 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Russia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 97: Russia 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 100: Rest of Europe 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 103: Rest of Europe 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 106: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 109: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 112: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
AUSTRALIA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- Chugai Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Forma Therapeutics, Inc.
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals
- Transgene SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 406 |
| Published | May 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 14.9 Billion |
| Forecasted Market Value ( USD | $ 25.2 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
